Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
Top Cited Papers
Open Access
- 10 February 2005
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 352 (6), 570-585
- https://doi.org/10.1056/nejmsa042657
Abstract
The costs, benefits, and cost-effectiveness of screening for human immunodeficiency virus (HIV) in health care settings during the era of highly active antiretroviral therapy (HAART) have not been determined.Keywords
This publication has 100 references indexed in Scilit:
- Treatment for Adult HIV InfectionJAMA, 2004
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseThe New England Journal of Medicine, 2001
- Virologic Response Associated With a Change in Protease Inhibitor TherapyArchives of Internal Medicine, 2000
- Factors Associated with Incomplete Virological Response to Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsThe New England Journal of Medicine, 1999
- Longitudinal Analysis of CD4 T Cell Counts, T Cell Reactivity, and Human Immunodeficiency Virus Type 1 RNA Levels in Persons Remaining AIDS‐Free despite CD4 Cell Counts < 200 for >5 YearsThe Journal of Infectious Diseases, 1997
- Feasibility of Human Immunodeficiency Virus Vaccine Trials in Homosexual Men in the United States: Risk Behavior, Seroincidence, and Willingness to ParticipateThe Journal of Infectious Diseases, 1996
- Feasibility of an Emergency Department–Based, Risk-Targeted Voluntary HIV Screening ProgramAnnals of Emergency Medicine, 1996
- The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infectionJAMA, 1994
- Who should be screened for HIV infection? A cost-effectiveness analysisArchives of Internal Medicine, 1993